scholarly journals Novel therapeutic modalities and drug delivery in pancreatic cancer – an ongoing search for improved efficacy

2012 ◽  
pp. 1-4
Author(s):  
Yuqing Zhang ◽  
Kei Satoh ◽  
Min Li
Keyword(s):  
Drug Delivery ◽  
Pancreatic Cancer ◽  
Therapeutic Modalities ◽  
Novel Therapeutic

A Systematic Study of Novel Drug Delivery Mechanisms and Treatment Strategies for Pancreatic Cancer

2021 ◽  
pp. 102539
Author(s):  
Umme Hani ◽  
Riyaz Ali M. Osmani ◽  
Ayesha Siddiqua ◽  
Shadma Wahab ◽  
Sadia Batool ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Pancreatic Cancer ◽  
Systematic Study ◽  
Treatment Strategies ◽  
Novel Drug

scholarly journals Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1781
Author(s):  
Gustavo A. Arias-Pinilla ◽  
Helmout Modjtahedi
Keyword(s):  
Pancreatic Cancer ◽  
Monoclonal Antibodies ◽  
Antibody Therapy ◽  
Therapeutic Targets ◽  
Poor Response ◽  
Therapeutic Agents ◽  
Therapeutic Interventions ◽  
Western World ◽  
Wide Range ◽  
Novel Therapeutic

Pancreatic cancer remains as one of the most aggressive cancer types. In the absence of reliable biomarkers for its early detection and more effective therapeutic interventions, pancreatic cancer is projected to become the second leading cause of cancer death in the Western world in the next decade. Therefore, it is essential to discover novel therapeutic targets and to develop more effective and pancreatic cancer-specific therapeutic agents. To date, 45 monoclonal antibodies (mAbs) have been approved for the treatment of patients with a wide range of cancers; however, none has yet been approved for pancreatic cancer. In this comprehensive review, we discuss the FDA approved anticancer mAb-based drugs, the results of preclinical studies and clinical trials with mAbs in pancreatic cancer and the factors contributing to the poor response to antibody therapy (e.g. tumour heterogeneity, desmoplastic stroma). MAb technology is an excellent tool for studying the complex biology of pancreatic cancer, to discover novel therapeutic targets and to develop various forms of antibody-based therapeutic agents and companion diagnostic tests for the selection of patients who are more likely to benefit from such therapy. These should result in the approval and routine use of antibody-based agents for the treatment of pancreatic cancer patients in the future.

scholarly journals Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy

Materials ◽  
2021 ◽  
Vol 14 (11) ◽  
pp. 3083
Author(s):  
Cristiana Maria Grapa ◽  
Lucian Mocan ◽  
Dana Crisan ◽  
Mira Florea ◽  
Teodora Mocan
Keyword(s):  
Drug Delivery ◽  
Pancreatic Cancer ◽  
Targeted Delivery ◽  
Drug Toxicity ◽  
Treatment Options ◽  
Tumor Stroma ◽  
Chemotherapy Response ◽  
Rising Incidence ◽  
Tumor Accumulation ◽  
Accumulation Ability

As the increase in therapeutic and imaging technologies is swiftly improving survival chances for cancer patients, pancreatic cancer (PC) still has a grim prognosis and a rising incidence. Practically everything distinguishing for this type of malignancy makes it challenging to treat: no approved method for early detection, extended asymptomatic state, limited treatment options, poor chemotherapy response and dense tumor stroma that impedes drug delivery. We provide a narrative review of our main findings in the field of nanoparticle directed treatment for PC, with a focus on biomarker targeted delivery. By reducing drug toxicity, increasing their tumor accumulation, ability to modulate tumor microenvironment and even improve imaging contrast, it seems that nanotechnology may one day give hope for better outcome in pancreatic cancer. Further conjugating nanoparticles with biomarkers that are overexpressed amplifies the benefits mentioned, with potential increase in survival and treatment response.

Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer

2013 ◽  
Vol 330 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Muxing Kang ◽  
Biao Jiang ◽  
Bin Xu ◽  
Wenjie Lu ◽  
Qingqu Guo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Pancreatic Cancer

pH-Triggered release of gemcitabine from polymer coated nanodiamonds fabricated by RAFT polymerization and copper free click chemistry

2016 ◽  
Vol 7 (40) ◽  
pp. 6220-6230 ◽  
Author(s):  
Haiwang Lai ◽  
Mingxia Lu ◽  
Hongxu Lu ◽  
Martina H. Stenzel ◽  
Pu Xiao
Keyword(s):  
Drug Delivery ◽  
Pancreatic Cancer ◽  
Click Chemistry ◽  
Raft Polymerization ◽  
Stimuli Responsive ◽  
Triggered Release

Prodrug (gemcitabine)-based polymer coated nanodiamonds as stimuli-responsive drug delivery platforms for the treatment of pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document